Adia Nutrition Inc. Completes Independent Audit with Astra Audit and Advisory LLC., Prepares to File for OTCQB Uplisting
Adia Nutrition Inc. (OTC Pink: ADIA) has successfully completed an independent audit with Astra Audit and Advisory , a PCAOB-registered auditing firm, positioning the company for uplisting to the OTCQB market. This milestone represents a significant step toward enhanced transparency and investor confidence.
The company, focused on advanced stem cell therapies and nutritional wellness, provides cutting-edge treatments including Umbilical Cord Stem Cell (UCB-SC) treatments and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) nationwide. The planned uplisting to OTCQB is expected to provide greater liquidity and market exposure, supporting the company's expansion of its clinic network and development of innovative therapies for conditions like Multiple Sclerosis.
Adia Nutrition Inc. (OTC Pink: ADIA) ha completato con successo un audit indipendente con Astra Audit and Advisory, una società di revisione registrata presso la PCAOB, posizionando l'azienda per un passaggio al mercato OTCQB. Questo traguardo rappresenta un passo significativo verso una maggiore trasparenza e fiducia degli investitori.
L'azienda, focalizzata su terapie avanzate con cellule staminali e benessere nutrizionale, offre trattamenti all'avanguardia, inclusi i trattamenti con cellule staminali da cordone ombelicale (UCB-SC) e il trapianto di cellule staminali ematopoietiche autologhe (aHSCT) a livello nazionale. Il previsto passaggio all'OTCQB è destinato a fornire maggiore liquidità ed esposizione sul mercato, supportando l'espansione della rete di cliniche dell'azienda e lo sviluppo di terapie innovative per condizioni come la sclerosi multipla.
Adia Nutrition Inc. (OTC Pink: ADIA) ha completado con éxito una auditoría independiente con Astra Audit and Advisory, una firma de auditoría registrada en PCAOB, posicionando a la empresa para una cotización en el mercado OTCQB. Este hito representa un paso significativo hacia una mayor transparencia y confianza de los inversores.
La empresa, centrada en terapias avanzadas con células madre y bienestar nutricional, ofrece tratamientos de vanguardia, incluidos los tratamientos con células madre de cordón umbilical (UCB-SC) y el trasplante autólogo de células madre hematopoyéticas (aHSCT) a nivel nacional. Se espera que la cotización en OTCQB proporcione una mayor liquidez y exposición en el mercado, apoyando la expansión de la red de clínicas de la empresa y el desarrollo de terapias innovadoras para condiciones como la esclerosis múltiple.
Adia Nutrition Inc. (OTC Pink: ADIA)는 PCAOB에 등록된 감사 회사인 Astra Audit and Advisory와 독립 감사 를 성공적으로 완료하여 OTCQB 시장으로의 상장을 위한 기반을 마련했습니다. 이 이정표는 투명성 향상과 투자자 신뢰를 위한 중요한 단계입니다.
이 회사는 첨단 줄기 세포 치료 및 영양 건강에 중점을 두고 있으며, 제대혈 줄기 세포(UCB-SC) 치료와 자가 조혈 줄기 세포 이식(aHSCT) 등 최첨단 치료법을 전국적으로 제공합니다. OTCQB로의 상장은 더 큰 유동성과 시장 노출을 제공하여 회사의 클리닉 네트워크 확장과 다발성 경화증과 같은 질환에 대한 혁신적인 치료법 개발을 지원할 것으로 예상됩니다.
Adia Nutrition Inc. (OTC Pink: ADIA) a réussi à réaliser un audit indépendant avec Astra Audit and Advisory, une société d'audit enregistrée auprès de la PCAOB, positionnant ainsi l'entreprise pour une cotation sur le marché OTCQB. Cette étape représente un progrès significatif vers une plus grande transparence et une confiance accrue des investisseurs.
L'entreprise, axée sur les thérapies avancées par cellules souches et le bien-être nutritionnel, propose des traitements de pointe, y compris des traitements par cellules souches de cordon ombilical (UCB-SC) et des transplantations de cellules souches hématopoïétiques autologues (aHSCT) à l'échelle nationale. La cotation prévue sur l'OTCQB devrait offrir une plus grande liquidité et une meilleure visibilité sur le marché, soutenant l'expansion du réseau de cliniques de l'entreprise et le développement de thérapies innovantes pour des conditions telles que la sclérose en plaques.
Adia Nutrition Inc. (OTC Pink: ADIA) hat erfolgreich ein unabhängiges Audit mit Astra Audit and Advisory, einer bei der PCAOB registrierten Wirtschaftsprüfungsgesellschaft, abgeschlossen, wodurch das Unternehmen für eine Notierung im OTCQB-Markt positioniert wird. Dieser Meilenstein stellt einen bedeutenden Schritt in Richtung erhöhter Transparenz und Vertrauen der Investoren dar.
Das Unternehmen, das sich auf fortschrittliche Stammzelltherapien und Ernährungswohlbefinden konzentriert, bietet innovative Behandlungen an, darunter Behandlungen mit Nabelschnur-Stammzellen (UCB-SC) und autologe hämatopoetische Stammzelltransplantationen (aHSCT) im ganzen Land an. Die geplante Notierung im OTCQB wird voraussichtlich eine höhere Liquidität und Marktpräsenz bieten, was die Expansion des Kliniknetzwerks des Unternehmens und die Entwicklung innovativer Therapien für Erkrankungen wie Multiple Sklerose unterstützt.
- None.
- None.
Winter Park, Florida--(Newsfile Corp. - April 7, 2025) - Adia Nutrition Inc. (OTC Pink: ADIA), a pioneering force in advanced stem cell therapies and nutritional wellness, is proud to announce the successful completion of its independent audit, a crucial milestone that positions the company to file for uplisting to the OTCQB market. This achievement marks a significant step in Adia Nutrition's journey to enhance transparency, build investor confidence, and amplify shareholder value as it continues to revolutionize healthcare through its innovative treatment offerings and wellness solutions.
The audit, conducted with precision by Astra Audit and Advisory LLC., a PCAOB-registered auditing firm, was completed efficiently and thoroughly. This process reviewed the company's financials and operations, ensuring compliance with the heightened standards required for the OTCQB tier-a market that demands rigorous reporting and offers greater visibility compared to the OTC Pink market. The successful audit is a testament to Adia Nutrition's commitment to financial integrity as it scales its primary business of providing cutting-edge stem cell therapies, including Umbilical Cord Stem Cell (UCB-SC) treatments and Autologous Hematopoietic Stem Cell Transplantation (aHSCT), to patients nationwide.
"We are incredibly excited to reach this point," said Larry Powalisz, CEO of Adia Nutrition Inc. "Completing this audit is a vital step in our uplisting to the OTCQB, reflecting our team's dedication to excellence. This milestone not only strengthens our credibility but also supports our mission to deliver life-changing stem cell therapies to patients while creating value for our shareholders. As we accelerate our growth, we remain committed to advancing regenerative medicine and nutritional wellness with science-backed solutions."
The move to OTCQB highlights Adia Nutrition's focus on operational excellence and shareholder trust as it expands its network of clinics delivering advanced stem cell treatments and complementary nutritional products. With the audit finalized, the company is poised to swiftly advance its filing process with the OTC Markets Group, enhancing its market presence and investor appeal. This uplisting will provide greater liquidity and exposure, supporting Adia Nutrition's ambitious goals of treating patients with innovative therapies, such as UCB-SC for inflammation and aHSCT for autoimmune conditions like Multiple Sclerosis, while driving sustainable growth and long-term value for its stakeholders.
For questions, inquiries or further information, please contact Larry Powalisz at ceo@adiamed.com or 321-788-0850.
About ADIA Nutrition Inc.:
Adia Nutrition Inc. is a publicly traded company (OTC Pink: ADIA) dedicated to revolutionizing healthcare and supplementation. With a focus on innovation and quality, the company has established two key divisions: a supplement division providing premium, organic supplements, and a medical division establishing Clinics that specialize in leading-edge stem cell therapies, most significantly Umbilical Cord Stem Cells (UCB-SC) and Autologous Hematopoietic Stem Cell Transplantation (aHSCT) treatments. Through these divisions, Adia Nutrition Inc. is committed to empowering individuals to live their best lives by addressing both nutritional needs and groundbreaking medical treatments.
Website: www.adianutrition.com
Website: www.adiamed.com
Website: www.adialabs.com
Website: www.biolete.com
Website: www.cementfactory.co
Twitter (X): @ADIA_Nutrition
Safe Harbor: This Press Release contains forward-looking statements within the meaning of Section 27A of the Securities Act of 1933 and Section 21E of the Securities Exchange Act of 1934. These forward-looking statements are based on the current plans and expectations of management and are subject to a few uncertainties and risks that could significantly affect the company's current plans and expectations, as well as future results of operations and financial condition. A more extensive listing of risks and factors that may affect the company's business prospects and cause actual results to differ materially from those described in the forward-looking statements can be found in the reports and other documents filed by the company with the Securities and Exchange Commission and OTC Markets, Inc. OTC Disclosure and News Service. The company undertakes no obligation to publicly update or revise any forward-looking statements, because of new information, future events or otherwise.
To view the source version of this press release, please visit https://www.newsfilecorp.com/release/247296
FAQ
What is the significance of Adia Nutrition's (ADIA) independent audit completion?
What are the main treatment offerings of Adia Nutrition (ADIA)?
How will the OTCQB uplisting benefit ADIA shareholders?
Which auditing firm conducted ADIA's independent audit in April 2025?
